Complement 3 Glomerulopathy (C3G) Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The complement 3 glomerulopathy (C3G) treatment market size was valued at USD 0.99 billion in 2025 and is estimated to grow from USD 1.11 billion in 2026 to reach USD 1.93 billion by 2031, at a CAGR of 11.75% during the forecast period (2026-2031). This report is segmented by Therapy Type (Supportive and Renoprotective Therapy [ACE Inhibitors and Angiotensin Receptor Blockers, and More], Immunosuppressive Therapy, and More), Disease Subtype (C3GN, Dense Deposit Disease), Route of Administration (Oral and More), Distribution Channel (Hospital Pharmacies and More), and Geography. Forecasts are Provided in Terms of Value (USD).

Global Complement 3 Glomerulopathy (C3G) Treatment Market Trends and Insights

Approval Of Targeted Complement Therapies And Renal Endpoints

The United States approved iptacopan in March 2025 and pegcetacoplan on July 28, 2025, giving patients with C3G 2 approved disease-specific options. Iptacopan reduced the 24-hour urine protein-to-creatinine ratio by 35.1% relative to placebo at 6 months in APPEAR-C3G. In VALIANT, pegcetacoplan reduced UPCR by 68% at 26 weeks, and 71% of treated patients achieved complete C3c-staining clearance on kidney biopsy. The Complement 3 Glomerulopathy (C3G) treatment market benefits because proteinuria reduction has supported a more practical regulatory pathway for therapies in a very small patient population. The European Commission approved pegcetacoplan in January 2026 for adults and adolescents aged 12 years and older with C3G or primary IC-MPGN. This close timing between U.S. and European access reduces the usual launch gap for rare renal treatments and raises the value of outcome data for the Complement 3 Glomerulopathy (C3G) treatment market.

Expansion Of Diagnostic Testing And Registries

A C3G diagnosis relies on immunofluorescence staining, electron microscopy, and a complement biomarker assessment that can include AP50, CH50, serum C3, sC5b-9, Factor B, Ba, and Bb. Testing can also include C3 nephritic factor, anti-Factor H, and sequencing of complement-related genes, which helps clinicians identify the mechanism involved. KDIGO has called for composite panels that bring functional assays, activation fragments, autoantibodies, and integrated data together rather than depending on one marker. Mayo Clinic Laboratories offers a 15-gene panel that includes C3, CFH, CFHR1-5, CFB, and CFI for relevant complement disorders. Better testing can identify patients whose disease has been missed or classified incorrectly, expanding the diagnosed population available to the Complement 3 Glomerulopathy (C3G) treatment market. European registries also provide a longer record of disease characteristics and care patterns that can help clinicians and payers assess treatment use across countries.

Ultra-Rare Population And Fragmented Diagnosis

C3G affects 1-5 individuals per million people each year worldwide, which limits absolute treatment volume even as available therapies expand. Small trials can support approval when endpoints are persuasive, but they leave clinicians and payers with less long-term evidence than they may have for common kidney diseases. A fragmented diagnostic pathway compounds this issue in regions that lack coordinated biopsy, complement testing, and genetic services, slowing access to the Complement 3 Glomerulopathy (C3G) treatment market. Patients may remain on generic immunosuppression when the underlying complement mechanism is not established. The resulting gap is particularly important in developing Asia, South America, and parts of the Middle East and Africa, where specialist access and reimbursement systems remain uneven.

Other drivers and restraints analyzed in the detailed report include:

• Post-Transplant Care And Tissue-Targeted Approaches
• Rising Use of Integrated Renal Outcome Endpoints
• Infection Risk And Long-Term Evidence Gaps

Segment Analysis

Complement-targeted agents held 52.31% of the C3G treatment share in 2025. Their lead reflects the arrival of iptacopan and pegcetacoplan after a period when no approved disease-specific therapy was available. Supportive and renoprotective care remains important, including ACE inhibitors, angiotensin receptor blockers, and SGLT2 inhibitors. Immunosuppressive drugs such as corticosteroids, mycophenolate mofetil, and rituximab are still used because clinicians know these therapies, and they can cost less. Their role is changing because controlled long-term evidence for kidney preservation in C3G remains limited.

Gene and RNA-based therapy is the fastest-growing segment at a 13.58% CAGR from 2026 to 2031. This part of the Complement 3 Glomerulopathy (C3G) treatment industry is being developed around less frequent subcutaneous dosing, including quarterly or twice-yearly schedules. Arrowhead reported 90% mean serum Factor B knockdown after a single 400 mg ARO-CFB dose in its Phase 1/2a study. SanegeneBio received FDA Orphan Drug Designation in October 2025 for SGB-9768, an RNAi therapy targeting complement C3 mRNA. Plasma therapy and tissue-targeted inhibitors remain smaller categories, but they can support patients who need bridging treatment or have specific autoantibody patterns.

C3 Glomerulonephritis accounted for 66.24% of the Complement 3 Glomerulopathy (C3G) treatment market size in 2025. Its larger presence reflects its stated prevalence among C3G cases and its inclusion in the populations for both approved agents. VALIANT included adults and adolescents aged 12 years and older, which broadened the evidence base across C3GN patients. This segment benefits from more established clinical recognition and a direct link to the current approved treatment pathway. It will remain central to prescribing volume while diagnosis improves.

Dense Deposit Disease is forecast to grow at a 13.22% CAGR from 2026 to 2031. Its more aggressive clinical course can prompt earlier consideration of targeted therapy when clinicians identify its distinct complement profile. DDD is often associated with C3 nephritic factor positivity, dense intramembranous deposits, and earlier progression to end-stage renal disease. The Complement 3 Glomerulopathy (C3G) treatment industry is responding with programs that can address patients whose disease was less visible in earlier trials. Between 10% and 20% of older adults with C3G have an associated monoclonal paraprotein, which can require clone-directed treatment before or alongside complement inhibition. That sequence can delay treatment initiation for a subset of older patients.

Complete Report Scope:

• By Therapy Type
  • Supportive and Renoprotective Therapy
    • ACE Inhibitors and Angiotensin Receptor Blockers
    • Sodium-Glucose Cotransporter-2 Inhibitors
    • Lipid-Lowering Therapy
    • Diuretics and Blood-Pressure Management
  • Immunosuppressive Therapy
    • Corticosteroids
    • Mycophenolate Mofetil
    • Cyclophosphamide
    • Rituximab
    • Calcineurin Inhibitors
  • Complement-Targeted Therapy
    • Factor B Inhibitors
    • C3 and C3b Inhibitors
    • C5 Inhibitors
    • Factor D Inhibitors
    • MASP-3 Inhibitors
    • C5aR1 Antagonists
    • Recombinant Factor H Therapies
    • Dual-Target Complement Inhibitors
    • Tissue-Targeted Complement Inhibitors
  • Plasma Therapy
  • Gene and RNA-Based Therapy
• By Disease Subtype
  • C3 Glomerulonephritis
  • Dense Deposit Disease
• By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Other Routes of Administration
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.61% of the Complement 3 Glomerulopathy (C3G) treatment market share in 2025. The United States accounted for most of this regional position because it had the largest diagnosed population, an early reimbursement response, and a high concentration of complement-specialist nephrology programs. Canada and Mexico have patients with C3G, but their specialist networks and diagnostic capacity are smaller. The January 2026 European approval of pegcetacoplan can reduce the usual lead time that U.S. launches have in rare renal diseases.

Europe has an established diagnostic and research structure through the European Reference Network for Rare Kidney Diseases. The CompCure sub-registry had enrolled 350 patients with C3G or IC-MPGN from more than 20 countries by the end of 2025. The broader ERKReg registry includes more than 70,000 patients with rare kidney diseases across 24 European countries and can support local evidence generation, treatment planning, and payer discussions. Access will still vary because national benefit assessments in Germany, France, and the United Kingdom can determine the pace of use.

Asia-Pacific is forecast to grow at a 13.25% CAGR from 2026 to 2031. Expanding specialist nephrology units and regulatory reviews for iptacopan in Japan and China support the region’s position. A survey of Japanese nephrologists reported corticosteroid use in 64% of cases, ACEi or ARB use in 68%, and SGLT2 inhibitor use in 25%. SanegeneBio started a Phase 2 study of SGB-9768 in China in March 2025. The Complement 3 Glomerulopathy (C3G) treatment market will remain limited in the Middle East and Africa and South America by less-developed reimbursement and diagnostic systems. However, GCC countries, Brazil, and Argentina are increasing specialist interest.

List of Companies Covered in this Report:

• Alexion Pharmaceuticals
• Amgen
• Amyndas Pharmaceuticals
• Apellis Pharmaceuticals
• Arrowhead Pharmaceuticals
• AstraZeneca
• BioCryst Pharmaceuticals
• Eleva Biologics
• GlaxoSmithKline
• Kira Pharmaceuticals
• Novartis
• NovelMed Therapeutics
• Novo Nordisk
• Omeros Corporation
• Pfizer
• Q32 Bio
• Regeneron Pharmaceuticals
• Roche
• Sanofi
• Swedish Orphan Biovitrum
• Teva Pharmaceutical Industries
• Travere Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support